Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Trial Profile

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs CC 223 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TORCH
  • Sponsors Antengene Corporation
  • Most Recent Events

    • 07 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 20 Jul 2018 Status changed from planning to recruiting, according to a STA Pharmaceutical media release.
    • 19 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top